Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma

By Hartmann M.   Fedders M.   Schneider A.   Kath R.   Camara O.   Oelschläger H.  

Journal of Cancer Research and Clinical Oncology, Vol. 133, Iss. 9, 2007-09 ,pp. : 619-625

Springer Publishing Company

Access to resources Recommend Favorite

The Use of Paclitaxel and Platinum-Based Chemotherapy in Uterine Papillary Serous Carcinoma

By Zanotti K.M.   Belinson J.L.   Kennedy A.W.   Webster K.D.   Markman M.  

Gynecologic Oncology, Vol. 74, Iss. 2, 1999-08 ,pp. : 272-277

Elsevier

Access to resources Recommend Favorite

Experience with Platinum-Paclitaxel Chemotherapy in the Initial Management of Papillary Serous Carcinoma of the Peritoneum

By Kennedy A.W.   Markman M.   Webster K.D.   Kulp B.   Peterson G.   Rybicki L.A.   Belinson J.L.  

Gynecologic Oncology, Vol. 71, Iss. 2, 1998-11 ,pp. : 288-290

Elsevier

Access to resources Recommend Favorite

Paclitaxel-Anthracycline Combination Chemotherapy in Relapsing Advanced Ovarian Cancer after Platinum-Based Chemotherapy: A Pilot Study

By Kurtz J.E.   Deplanque G.   Duclos B.   Eichler F.   Giron C.   Limacher J.M.   Herbrecht R.   Maloisel F.   Oberling F.   Bergerat J.P.   Dufour P.  

Gynecologic Oncology, Vol. 70, Iss. 3, 1998-09 ,pp. : 414-417

Elsevier

Access to resources Recommend Favorite

Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: The prediction value of ERCC1 and Tau expression

By                

International Journal of Oncology, Vol. 44, Iss. 5, 2014-01 ,pp. : 1736-1744

Spandidos Publications

Access to resources Recommend Favorite